am wondering if it is possible to get feedback on this article from our
good doctor. Thanks
MULTIPLE SCLEROSIS (MS) PATIENTS IMPROVE AFTER STEMCELL USE


Las Vegas, NV 2/21/2006 1:46 AM GMT (TransWorldNews - Top Story)
Four MS patients, all wheelchair bound, have reported the following results
two weeks after the stem cell / placenta implant (the Implant)

1. Cold feet needing various forms of heating during the night become warm
with no need of heating.
2. Substantial improvement or disappearance of spasticity.
3. Being able, while in the wheelchair, to move their legs with relative
ease.
4. Urinary frequency markedly reduced, and in one case the use of self
catheterization a painful and infection prone procedure, discontinued
5. Initiating or increasing walking distance with the help of a walker.

These results were obtained by Nevada physicians doing the implant procedure
in their private offices. Accordingly the use of the implant will be
extended to other conditions, besides MS namely Alzheimer's, strokes,
juvenile diabetes type I, retinitis pigmentosa (RP), macular degeneration
also in children/adolescents with autism and Rett's syndrome. There is also
growing interest in using the Implant as an anti-aging/aging-control
procedure, placenta having gained already the reputation of being "the
Fountain of Youth from the Womb!"

However our main interest now is in MS, and our first objective is to have
the placenta implant used in 10+ MS patients, hoping to collect enough data,
to enable us to submit to the FDA, the Center of Biological Research (CBER)
an Investigational New Drug (IND) application for a biological product.

An interesting proposal had been received from a main TV chain by which they
would be interested in a story, where subjects programmed for the implant
would be examined by specialized physicians, before and up to three months
after the procedure. This proposal would give them also the right to film
among others the whole Implant procedure.

STEM CELL PHARMA INC (SCPI)

SCPI is a privately held biotechnology corporation formed May 2005 in Las
Vegas. SCPI has acquired from its President, Alfred T. Sapse MD "(Ret) the
world wide rights to a proprietary technology titled Amnion Stem Cells,
Telomerase Enhanced Placenta Implant (The Implant)." This procedure would
enable amnion stem cells/placenta with the potential to differentiate into a
wide variety of different organs, including: the heart, liver, and brain, be
transferred from the donor, the placenta of the new born, to the recipient
in less than three hours. This technique does not need freezing of the
cells, and subsequent thawing. Subsequently the multiplication or the
increase many fold in the number of stem cells would not be done by
culturing them, in a medium often containing rat cells "the feeder" and
subject to contamination, as it is being done in many research, but being
cultured in the best feeder there is namely in the body of the recipient.
The role of enhancing telomerase, an enzyme, which extends the number of
multiplications of the stem cells is vital since otherwise these cells
multiply only twenty times and die. In this regard a statement by Makki
(2005) that the amnion cells lack telomerase activity is incorrect.

The amnion stem cells do have telomerase activity, which activity is
increased through a proprietary technique that assures the multiplication of
the telomerase many times over (Suggested reading: Amniotic Fluid Cells and
Human Stem Cell Research - A New Connection by AR Prusa M. Hengstschläger
Med. Sci. Monit. 2002: 8(11):RA 253-257)

Another amazing capability of the amnion cells is in its fetal tissue
engineering ie. in building up new tissues. Two (2) cc of amniotic fluid
rich in stem cells, might be able to correct congenital defects if implanted
immediately after birth in the body of a new born with such defects (ibid).

So where do we go from here? We believe that by proceeding with the program
of stem cell/placenta implants, as described above, we will be able to bring
important new date in the use of amniotic stem cells, which eventually would
shorten the time of certain research now in progress and provide new
treatments much sooner than anticipated.

For more information please contact:

Alfred T. Sapse MD (ret) c/o
Stem Cell Pharma Inc., Las Vegas, NV
Phone: (702) 734-6814
Fax: (702) 733-9505

----------------------------------------------------------------------
To sign-off Parkinsn send a message to: mailto:[log in to unmask]
In the body of the message put: signoff parkinsn